Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Debt / NOTE 3.250% 7/0
-
Market price (% of par)
-
99.25%
-
Total 13F principal
-
$96,946,832
-
Principal change
-
+$4,645,677
-
Total reported market value
-
$96,458,698
-
Number of holders
-
17
-
Value change
-
+$4,661,082
-
Number of buys
-
7
-
Number of sells
-
6
Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q1 2023
As of 31 Mar 2023,
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 was held by
17 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$96,946,832
in principal (par value) of the bond.
The largest 10 bondholders included
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), OAKTREE CAPITAL MANAGEMENT LP, Kohlberg Kravis Roberts & Co. L.P., Atlas Merchant Capital LLC, Russell Investments Group, Ltd., MORGAN STANLEY, PIPER SANDLER & CO., WELLS FARGO & COMPANY/MN, STATE STREET CORP, and GAMCO INVESTORS, INC. ET AL.
This page lists
17
institutional bondholders reporting positions
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.